MiNK Therapeutics社、Genedata Biologicsを導入：iNKT細胞療法（InvariantナチュラルキラーT細胞）の研究開発を効率化
MiNK uses Genedata Biologics to streamline the identification, engineering, and characterization of novel cell therapy products
December 1, 2021
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that MiNK Therapeutics has partnered with Genedata to deploy its workflow platform, Genedata Biologics®, for support of their iNKT cell therapy pipeline programs.
“Given their track-record of success, Genedata’s platform was the clear choice to support and integrate our full cell therapy discovery and development efforts,” said Marc Van Dijk, Ph.D., Chief Technology Officer of MiNK Therapeutics. “This will further augment the ability for our cell and gene therapy scientists to capture, process, and interpret R&D data, streamlining our efforts as we rapidly advance our growing cell therapy programs.”
Genedata Biologics provides fully integrated support for biopharma research workflows, which MiNK will utilize as their backbone system to streamline the identification, engineering, and characterization of novel cell therapy products. The Genedata Biologics platform will help enable swifter delivery of naturally derived and engineered receptors, specifically T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to enhance human immune effector cells to fight cancer.
“We are excited that MiNK Therapeutics, a leading cell therapy company developing unique immune therapies for patients with cancer, has decided to roll out Genedata Biologics to scale up their cell therapy R&D programs,” said Othmar Pfannes, Ph.D., CEO of Genedata. “This further validates our success in supporting the quickly growing cell and gene therapy market. We remain committed to developing our platform to keep up with the latest scientific innovations by providing cutting-edge support for novel cell therapies. We look forward to a long and productive partnership helping MiNK Therapeutics bring innovative cell therapies to society.”
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.